Maxim Group started coverage on shares of Virios Therapeutics (NASDAQ:VIRI – Free Report) in a research report report published on Thursday morning, Benzinga reports. The firm issued a buy rating and a $1.00 target price on the stock.
Virios Therapeutics Trading Up 4.4 %
Shares of VIRI stock opened at $0.26 on Thursday. The firm’s 50 day moving average is $0.33 and its 200 day moving average is $0.44. The stock has a market capitalization of $5.01 million, a P/E ratio of -0.96 and a beta of 1.62. Virios Therapeutics has a 12 month low of $0.16 and a 12 month high of $2.42.
Virios Therapeutics (NASDAQ:VIRI – Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. On average, equities analysts predict that Virios Therapeutics will post -0.27 EPS for the current year.
About Virios Therapeutics
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Featured Articles
- Five stocks we like better than Virios Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- Darden Stock Up After Q4 Earnings Beat, Cautious FY25 Outlook
- The 3 Best Fintech Stocks to Buy Now
- Celsius Stock: Why Piper Sandler Forecasts a 50% Surge
- Using the MarketBeat Dividend Tax Calculator
- Accenture’s Stock Earnings Reveal an AI-Powered Growth Strategy
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.